Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-12 5:16 pm Purchase | 2020-12-31 | 13G | Forma Therapeutics Holdings, Inc. FMTX | Lilly Ventures Fund I LLC | 2,404,069 5.200% | 2,404,069 (New Position) | Filing History |
| 2021-02-12 5:08 pm Sale | 2020-12-31 | 13G | Surface Oncology, Inc. SURF | Lilly Ventures Fund I LLC | 3,447,817 8.500% | -36,801 (-1.06%) | Filing History |
| 2021-02-12 4:59 pm Sale | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Lilly Ventures Fund I LLC | 102,742 5.400% | -3,227 (-3.04%) | Filing History |
| 2020-06-08 4:04 pm Sale | 2020-05-11 | 13D | Protagonist Therapeutics, Inc. PTGX | Lilly Ventures Fund I LLC | 1,559,060 4.500% | -540,422 (-25.74%) | Filing History |
| 2020-02-13 4:17 pm Sale | 2019-12-31 | 13G | Sutro Biopharma, Inc. STRO | Lilly Ventures Fund I LLC | 968,161 4.200% | -572,652 (-37.17%) | Filing History |
| 2020-02-13 4:17 pm Purchase | 2019-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Lilly Ventures Fund I LLC | 105,968 9.100% | 656 (+0.62%) | Filing History |
| 2020-02-13 4:17 pm Purchase | 2019-12-31 | 13G | Surface Oncology, Inc. SURF | Lilly Ventures Fund I LLC | 3,484,618 12.500% | 30,741 (+0.89%) | Filing History |